Navigation Links
US Cancer Generics Market Outlook 2022
Date:3/28/2017

LONDON, March 28, 2017 /PRNewswire/ -- "US Cancer Generics Market Outlook 2022" report gives comprehensive insight on the various indicators and trend analysis related to the emergence and integration of cancer generics drugs in mainstream pharmaceutical market in US. The report analyzes various clinical and non-clinical parameters responsible for the growth on cancer generics drugs in recent years. The introduction of generics has resulted in saving of billions of dollars for various stake holders involved US cancer drug market. It is expected that total savings from generics in cancer therapy (in treatment & post treatment) will surpass US$ 30 Billion by 2022 and will further give the required thrust to adoption of generics drugs in cancer therapy as compare to prescribed branded drugs.

Even though most of the attention and spending in the oncology segment in the US has been focused on the remarkable scientific inventions of the newer targeted drugs but the overburdening of the economic high cost of cancer drugs has made US to follow up the line of generics. Certainly, after the existence of Hatch-Waxman Act, the entries of generic products were acceptable between the Americans.

The beneficial aspects of generic regimens are already well established, as the delivery of equal therapeutic efficacy in low price is the principal aim of cancer generics. The cost for patented oncological drugs and the generic drugs have wide gap which is getting shorter with the emerging patent cliff for cancer drugs in US and the arrival of the cancer generics era.

Concerning the cost, indeed cancer generics provide an exceptional solution towards high cost, yet the scenario is different for the Americans. However, in US cancer generics cost much higher in contrary to the other nations, reason being is the no negotiation mode of government in the pharmaceutical sector. The prices paid for generics in US are many fold higher than developing countries like India and China.

Certainly, among the developed nations the usage and prescription of generics is quite higher depicting the greater medical needs due to overburden of massive diseases and cancer is one of them. The demand for cancer generics is so high that the trend has created a shortage landscape. It is a part of the problem of the scarcity of generics across all medical specialties, but its oncology is particularly vulnerable. The reason of the shortages is multi-factorial but is largely economic and is due to the lack of incentives to produce generics.

"US Cancer Generics Market Outlook 2022" report highlights:

- Introduction to Cancer Generics
- US Generic Drugs Legislature
- US Health Insurance Scenario & Cancer
- Aspects of Branded & Non-Branded Generics
- US Cancer Generics Market Overview

Download the full report: https://www.reportbuyer.com/product/4730953/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/us-cancer-generics-market-outlook-2022-300430559.html


'/>"/>
SOURCE ReportBuyer
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
2. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
3. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
4. RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
5. RuiYi et Genor BioPharma collaborent au développement du RYI-008 en Chine, un nouveau traitement contre les maladies auto-immunes et le cancer
6. Cancer Vaccine Partnering Terms and Agreements
7. MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of Noncoding Micro RNAs for the Treatment of Liver Cancer
8. RAD Technology Medical Systems Delivers Innovative Time Saving Modular Construction At New Swedish Cancer Institute Facility
9. National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill
10. Puerto Ricos Caribbean Imaging and Radiation Therapy Center Orders Elektas New Versa HD System for Treatment of Cancer Patients
11. New Data Validates CyberKnife SBRT for Prostate Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2019)... ... July 10, 2019 , ... ... double-blind, placebo controlled clinical study from Ohio State University Wexner Medical Center ... containing urolithins, fulvic acid, and micro minerals. Natreon is committed to continued ...
(Date:7/10/2019)... ... July 10, 2019 , ... DidCBDWork.com is ... for the past 18 months, does CBD actually work? It seems like depending on ... oil. , DidCBDWork.com instead aims to get testimonials of real CBD users, who ...
(Date:7/9/2019)... FALLS CHURCH, Va. (PRWEB) , ... July 10, ... ... Firms, and Their Suppliers, **An interactive workshop presented by Cerulean Associates LLC and ... Bethesda, MD, https://www.fdanews.com/fdadataintegrity , Early Bird Savings: Register by Sept. 23 ...
Breaking Medicine Technology:
(Date:7/9/2019)... ... July 10, 2019 , ... Women's Excellence is excited to offer laser vaginal rejuvenation. Laser ... such as , painful sex , vaginal dryness ... , urinary urgency , vaginal pH imbalances , recurrent ...
(Date:7/9/2019)... ... July 09, 2019 , ... A2LA is pleased to announce the accreditation ... oils, and solids. GEL Laboratories is based in Charleston, South Carolina, and is the ... first laboratory in the field of environmental testing to expand their scope to include ...
(Date:7/9/2019)... Ohio and MT. PROSPECT, Ill. (PRWEB) , ... ... ... of patient flow, staff workflow, and asset tracking technology, today announced a validated ... call platform. , Midmark RTLS has been enhancing Rauland’s nurse call platform with ...
(Date:7/9/2019)... ... July 09, 2019 , ... ... it is expanding to the Canadian marketplace through a new strategic partnership with ... pig health and production management technology to Canada’s swine industry. The partnership is ...
(Date:7/9/2019)... ... July 08, 2019 , ... East Valley Implant and Periodontal Center (EVIP) ... the East Valley of Arizona. With two impressive practices in Mesa and Scottsdale, the ... Established in 2003, EVIP is led by founder and practicing periodontist Dr. Todd Jorgenson. ...
Breaking Medicine News(10 mins):